Projects per year
Personal profile
Expertise
Project: " Targeting of tumor subpopulations in Multiple Myeloma: protein/gene expression analysis of residual cancer cells and targeting of these cells using nanobodies"
I obtained a Master in Biomedical Sciences at the Free University of Brussels (Vrije Universiteit Brussel, VUB) in 2011. I started my PhD in the lab of Hematology and Immunology (HEIM) under the supervision of Prof. Karin Vanderkerken focusing on the role of the bone marrow microenvironment in multiple myeloma drug resistance. I participated in an EU FP7 project (OVER-MyR) and investigated different cell types that contribute to myeloma disease including myeloid-derived suppressor cells (supervised by Prof. Els Van Valckenborgh), cancer associated fibroblasts (supervised by Prof. Eline Menu and Prof. Angelo Vacca) and mesenchymal stromal cells (supervised by Prof. Ivan Van Riet). In 2016, I obtained a FWO grant to continue my work as a post-doctoral researcher at the HEIM department and in 2018I became assistant professor (10%) at the VUB.
My project focuses on the use of antigen-specific nanobodies to target residual disease in myeloma and prevent relapse of patients. In collaboration with Prof Peter Croucher (Garvan Institute, Sydney, Australia), we investigate myeloma cell dormancy in vitro and in vivo. Nationally, I closely collaborate with Profs Nick Devoogdt and Matthias D’Huyvetter for the development and characterization of AXL- and CS1 specific nanobodies to target minimal residual disease in myeloma by targeted radionuclide therapy (TRNT).
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
FWOSB225: Liquid biopsy–based detection of genetic and epigenetic drivers of resistance to CD38‑, BCMA‑, and GPRC5D‑directed immunotherapies in multiple myeloma (LIQUIMM)
Calliauw, E. (Mandate), De Veirman, K. (Administrative Promotor), Van Riet, I. (CoI (Co-Promotor)) & De Becker, A. (CoI (Co-Promotor))
1/11/26 → 31/10/30
Project: Fundamental
-
OZR4466: Compact-MRI: Aspect Imaging M3 for compact, user-friendly, high-resolution magnetic resonance imaging in mice
Van Ginderachter, J. (Administrative Promotor), Laoui, D. (CoI (Co-Promotor)), Movahedi, K. (CoI (Co-Promotor)), De Veirman, K. (CoI (Co-Promotor)) & Hernot, S. (CoI (Co-Promotor))
1/05/26 → 30/04/30
Project: Fundamental
-
ANI432: Interferon Signaling as a Regulator of Cancer Cell Dormancy and Immune Suppression in Multiple Myeloma
Vanderkerken, K. (Administrative Promotor) & De Veirman, K. (PI (Promotor, Principal Investigator))
1/10/25 → 30/09/29
Project: Fundamental
-
HERC66: 3D-CELLMAP: Unveiling complex cellular interactions in tissues through 3D super-resolution protein multiplex imaging
Movahedi, K. (Administrative Promotor), Rooman, I. (CoI (Co-Promotor)), Sermon, K. (CoI (Co-Promotor)), De Bundel, D. (CoI (Co-Promotor)), Fioravanti, A. (CoI (Co-Promotor)), Staels, W. (CoI (Co-Promotor)), Magez, S. (CoI (Co-Promotor)), Breckpot, K. (CoI (Co-Promotor)), De Kock, J. (CoI (Co-Promotor)), Laoui, D. (CoI (Co-Promotor)), Goyvaerts, C. (CoI (Co-Promotor)), Smolders, I. (CoI (Co-Promotor)), Van Ginderachter, J. (CoI (Co-Promotor)), Marcelino Rodrigues, R. (CoI (Co-Promotor)), De Leu, N. (CoI (Co-Promotor)), van Grunsven, L. (CoI (Co-Promotor)), Hernot, S. (CoI (Co-Promotor)), Peeters, E. (CoI (Co-Promotor)), Vanhaecke, T. (CoI (Co-Promotor)), De Veirman, K. (CoI (Co-Promotor)), Ruytinx, J. (CoI (Co-Promotor)), Van Schependom, J. (CoI (Co-Promotor)), Kortekaas, I. (CoI (Co-Promotor)) & Goossens, E. (CoI (Co-Promotor))
1/05/24 → 31/05/28
Project: Fundamental
-
OZR4286: Financiering MZW OZR: DELI-SORT: MACSQuant® Tyto for sterile DELicate Immune cells SORTing
Laoui, D. (Administrative Promotor), Vanginderachter, J. A. (CoI (Co-Promotor)), Magez, S. (CoI (Co-Promotor)), Tuyaerts, S. (CoI (Co-Promotor)), Fioravanti, A. (CoI (Co-Promotor)), Devoogdt, N. (CoI (Co-Promotor)), Van der Henst, C. (CoI (Co-Promotor)), Raes, G. (CoI (Co-Promotor)), Stijlemans, B. (CoI (Co-Promotor)), Hadadi, E. (CoI (Co-Promotor)), De Trez, C. (CoI (Co-Promotor)), Ruytinx, J. (CoI (Co-Promotor)), Brunner, J. (CoI (Co-Promotor)), De Groof, T. (CoI (Co-Promotor)) & De Veirman, K. (CoI (Co-Promotor))
24/04/24 → 24/04/28
Project: Fundamental
-
Adrenergic stimulation of bone marrow immunity differentially affects myeloma growth and immunotherapy responses
Satilmis, H., Verheye, E., Faict, S., Heestermans, R., De Becker, A., Vanderkerken, K., De Bruyne, E., Menu, E., Sloan, E. K. & De Veirman, K., 28 Oct 2026, In: Cancer Letters. 659, 12 p., 218802.Research output: Contribution to journal › Article › peer-review
Open Access -
AXL-Specific Single-Domain Antibodies: A Novel Diagnostic and Therapeutic Strategy in PDAC
Denis, A., Michiels, E., Baldan, J., Satilmis, H., Zhan, D., Vandewalle, N., De Bruyne, E., Menu, E., Vanderkerken, K., Breckpot, K., Devoogdt, N., Rooman, I. & De Veirman, K., 6 Feb 2026. 1 p.Research output: Unpublished contribution to conference › Poster
-
Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma
De Coster, M., Hyka, L., De Cock, S., Meeussen, S., Wang, Z., Tu, C., Hernot, S., Devoogdt, N., David, G., De Veirman, K., Vanderkerken, K., Menu, E., Zimmermann, P. & De Bruyne, E., 17 Jun 2026, In: Journal of extracellular vesicles. 15, 6, 19 p., e70325.Research output: Contribution to journal › Article › peer-review
Open Access -
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
Tu, C., Van der Vreken, A., Meeus, F., van den Broecke, L., Brons, J., De Veirman, K., Vanderkerken, K., De Bruyne, E., Breckpot, K. & Menu, E., Dec 2026, In: Experimental Hematology and Oncology. 15, 1, 6 p., 1.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus) -
IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma
Satilmis, H., Denis, A., Verheye, E., Van der Vreken, A., Zhan, D., Calliauw, E., Törngren, M., Eriksson, H., Faict, S., De Bruyne, E., Menu, E., Vanderkerken, K. & De Veirman, K., 4 May 2026, In: Journal of Experimental & Clinical Cancer Research. 45, 18 p., 172.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
RNA sequencing dataset of tasquinimod-treated LP1 cells
Maes, K. (Creator) & De Veirman, K. (Creator), ArrayExpress, 25 Jan 2023
Dataset
-
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages
Laoui, D. (Creator), Kancheva, D. (Creator), Satilmis, H. (Creator), Vandewalle, N. (Creator), Fan, R. (Creator), Bardet, P. (Creator), Clappaert, E. (Creator), Verstaen, K. (Creator), De Becker, A. (Creator), Vanderkerken, K. (Creator) & De Veirman, K. (Creator), NCBI Gene Expression Omnibus, 14 Nov 2024
Dataset
-
Dataset of AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Vandewalle, N. (Creator), Satilmis, H. (Creator), Verheye, E. (Creator), Wang, Y. (Creator), De Groof, T. (Creator), Bridoux, J. (Creator), Kerre, T. (Creator), De Beule, N. (Creator), De Becker, A. (Creator), De Bruyne, E. (Creator), Menu, E. (Creator), Vanderkerken, K. (Creator), Breckpot, K. (Creator), Devoogdt, N. (Creator) & De Veirman, K. (Creator), Theranostics, 15 Apr 2024
DOI: 10.7150/thno.91456, https://zenodo.org/records/15111364
Dataset
-
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
Menu, E. (Creator), Van der Vreken, A. (Creator), Tu, C. (Creator), De Bruyne, E. (Creator), van den Broecke, L. (Creator), Meeus, F. (Creator), Brons, J. (Creator), De Veirman, K. (Creator), Vanderkerken, K. (Creator) & Breckpot, K. (Creator), Gene Expression Omnibus (GEO), 11 Sept 2025
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307311
Dataset
-
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism
Menu, E. (Creator), Oudaert, I. (Creator), Vanderkerken, K. (Creator), De Veirman, K. (Creator), De Bruyne, E. (Creator), Van der Vreken, A. (Creator), Ates, G. (Creator), Massie, A. (Creator) & Maes, K. (Creator), DRYAD, 9 Mar 2026
Dataset
Prizes
-
ASH abstract achievement award
Satilmis, H. (Recipient), Denis, A. (Recipient), Verheye, E. (Recipient), De Bruyne, E. (Recipient), Menu, E. (Recipient), Törngren, M. (Recipient), Eriksson, H. (Recipient), Vanderkerken, K. (Recipient) & De Veirman, K. (Recipient), 31 Oct 2025
Prize: Prize (including medals and awards)
-
ASH abstract Achievement Award 2014
De Veirman, K. (Recipient), 6 Dec 2014
Prize: National/international honour
-
ASH abstract Achievement Award 2019
De Veirman, K. (Recipient), 2019
Prize: National/international honour
-
Best Poster Presentation
Vandewalle, N. (Recipient), Menu, E. (Recipient), De Bruyne, E. (Recipient), De Veirman, K. (Recipient), Breckpot, K. (Recipient) & Devoogdt, N. (Recipient), 2 Feb 2024
Prize: Prize (including medals and awards)
-
Best Poster Presentation BHS 2025
Van Hemelrijck, L. A. (Recipient), Wang, Y. (Recipient), Muylaert, C. (Recipient), Olsen, C. (Recipient), De Veirman, K. (Recipient), Vanderkerken, K. (Recipient), Menu, E. (Recipient) & De Bruyne, E. (Recipient), 7 Feb 2025
Prize: Prize (including medals and awards)
Activities
-
MAT2A targeting resets the aberrant methylation landscape and DNA damage response in multiple myeloma, uncovering new potential combination strategies.
Van Hemelrijck, L. A. (Speaker), Wang, Y. (Speaker), Muylaert, C. (Speaker), Olsen, C. (Speaker), Vanderkerken, K. (Speaker), De Veirman, K. (Speaker), Menu, E. (Speaker) & De Bruyne, E. (Speaker)
6 Feb 2026Activity: Talk or presentation › Talk or presentation at a conference
-
IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of Multiple Myeloma
Satilmis, H. (Speaker), Denis, A. (Contributor), Verheye, E. (Contributor), Van der Vreken, A. (Contributor), Zhan, D. (Contributor), Calliauw, E. (Contributor), Törngren, M. (Contributor), Eriksson, H. (Contributor), Faict, S. (Contributor), De Bruyne, E. (Contributor), Menu, E. (Contributor), Vanderkerken, K. (Contributor) & De Veirman, K. (Contributor)
6 Feb 2026Activity: Talk or presentation › Talk or presentation at a conference
-
AXL-specific Single-Domain Antibodies Modulate the Immune Microenvironment and Enhance Checkpoint Blockade in AML
Zhan, D. (Presenter), Vandewalle, N. (Contributor), Satilmis, H. (Contributor), Verheye, E. (Contributor), De Bruyne, E. (Contributor), Menu, E. (Contributor), Vanderkerken, K. (Contributor), Breckpot, K. (Contributor), Devoogdt, N. (Contributor) & De Veirman, K. (Contributor)
25 Sept 2025Activity: Talk or presentation › Talk or presentation at a conference
-
Pan cancer single-cell atlas of mouse and human tumor-associated dendritic cells
Caro, A. A. (Speaker), Kancheva, D. (Contributor), Bardet, P. (Contributor), Verheye, E. (Contributor), De Veirman, K. (Contributor), Coosemans, A. (Contributor) & Laoui, D. (Contributor)
9 Jun 2024Activity: Talk or presentation › Talk or presentation at a conference
-
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Vandewalle, N. (Presenter), Satilmis, H. (Contributor), Verheye, E. (Contributor), Wang, Y. (Contributor), De Groof, T. (Contributor), De Beule, N. (Contributor), kerre, T. (Contributor), De Beule, N. (Contributor), De Becker, A. (Contributor), De Bruyne, E. (Contributor), Menu, E. (Contributor), Vanderkerken, K. (Contributor), Breckpot, K. (Contributor), Devoogdt, N. (Contributor) & De Veirman, K. (Contributor)
12 Mar 2024Activity: Talk or presentation › Talk or presentation at a conference
Thesis
-
Assessment of antigen-binding domain parameters important for adequate CAR-T-cell activation: evaluating different SLAMF7-targeting nanobodies.
Meeus, F. ((PhD) Student), Hanssens, H. ((PhD) Student), De Veirman, K. (Co-promotor) & Devoogdt, N. (Promotor), Hanssens, H. (Advisor), 19 Jun 2020Student thesis: Master's Thesis
-
AXL and CS1: New targets in myeloma cell dormancy
De Veirman, K. (Promotor) & Benalla, S. ((PhD) Student), 21 Jun 2018Student thesis: Master's Thesis
-
Development of a NanoCAR approach for the treatment of multiple myeloma
Devoogdt, N. (Promotor), Breckpot, K. (Promotor), De Veirman, K. (Promotor) & Hanssens, H. ((PhD) Student), 10 Sept 2024Student thesis: Doctoral Thesis
-
Evaluation of the diagnostic and therapeutic potential of AXL-targeting nanobodies in cancer
Smets, I. T. ((PhD) Student), Devoogdt, N. (Co-promotor) & De Veirman, K. (Promotor), Vandewalle, N. (Advisor), 17 Jun 2022Student thesis: Master's Thesis
-
Mesenchymal Stromal Cell induced hedgehog signaling in Multiple Myeloma and its role in drug resistance
De Veirman, K. (Co-promotor) & Terwecoren, D. ((PhD) Student), 2013Student thesis: Master's Thesis